Cefixime%252520trihidrate

# Cefixime Trihydrate ## Overview Cefixime is a third-generation cephalosporin antibiotic. It exhibits broad-spectrum activity against many Gram-negative bacteria (including *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Neisseria gonorrhoeae*) but has limited activity against Gram-positive organisms (e.g., *Staphylococcus* species). It is available as oral tablets and oral suspension. ## Primary Indications * Uncomplicated gonorrhea (cervical, urethral, rectal). * Otitis media. * Pharyngitis and tonsillitis. * Acute exacerbations of chronic bronchitis. * Uncomplicated urinary tract infections (UTIs). ## Adult Dosing * **Uncomplicated Gonorrhea:** 800 mg orally as a single dose. * **Other Infections (e.g., UTI, Respiratory):** 400 mg daily, administered either as a single dose or in two divided doses of 200 mg every 12 hours. ## Pediatric Dosing * **General Dosage:** 8 mg/kg/day orally, administered as a single dose or in two divided doses of 4 mg/kg every 12 hours. * **Age/Weight Restrictions:** Typically used in children >6 months of age. * *Note: Always verify pediatric dosing by weight rather than age. Oral suspension is the preferred dosage form for pediatric patients.* ## Dose Adjustments * **Renal Impairment:** If CrCl <20 mL/min, reduce dose to 200 mg once daily. * **Hepatic Impairment:** No specific dosage adjustment guidelines provided; use with caution. ## Contraindications * Known hypersensitivity to cefixime or other cephalosporins. * History of anaphylaxis to penicillins or other beta-lactams (use with extreme caution or avoid due to risk of cross-reactivity). ## Adverse Effects * **Common:** Diarrhea (most frequent), abdominal pain, nausea, dyspepsia. * **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypersensitivity reactions (rash, urticaria, anaphylaxis), Stevens-Johnson syndrome, and hematologic abnormalities (e.g., transient neutropenia). ## Key Drug Interactions * **Warfarin/Anticoagulants:** May enhance the anticoagulant effect by altering gut microflora (vitamin K synthesis). Monitor INR. * **Probenecid:** May increase serum levels of cefixime by inhibiting renal tubular secretion; clinically significant in cases of renal impairment. ## Monitoring * Monitor for signs of hypersensitivity. * Assess stool frequency and consistency to identify *C. difficile* infection if severe, watery, or bloody diarrhea occurs. * Clinical response to therapy; monitor symptoms of the original infection to ensure efficacy. ## Clinical Pearls * **Bioavailability:** The tablet and suspension are not strictly bioequivalent; if switching formulations, clinical judgment is advised. * **Gram-positive coverage:** Cefixime is notably poor against *Streptococcus pneumoniae* and *Staphylococcus aureus* compared to earlier-generation cephalosporins; it should not be used as empiric therapy if these are the suspected pathogens. * **Administration:** May be taken with or without food. * **Gonorrhea treatment:** Due to rising resistance, Cefixime 800 mg is often used in combination with other agents (e.g., doxycycline) based on current CDC or local infectious disease treatment guidelines. *** *Disclaimer: This information is for educational purposes only. Always verify current prescribing information, institutional protocols, and patient-specific factors with verified medical references (e.g., Lexicomp, UpToDate, or the product insert) before prescribing or administering medication.*